Tumor-educated platelet as liquid biopsy in lung cancer patients

Lian, Ling; Lin, Fang; Ma, Xiaoting; Chen, Zhaoxin; Yu, Jing

doi:10.1016/j.critrevonc.2020.102863

Cited by 31 publications

(28 citation statements)

References 74 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Spatial and temporal heterogeneities are often responsible for many critical issues in the diagnosis and treatment of cancer patients, requiring the use of new, fast, more accurate, sensitive, and specific techniques, able to be a valuable addition to the available assessment methods in guiding the therapy management that best fits patient's individuality and tumor singularity. In today's era of precision oncology, minimally invasive liquid biopsies represent an extremely appealing approach to be implemented both at pre-treatment baseline and longitudinally as predictive markers during the course of tyrosine kinase inhibitors (TKI) treatment [53,59,62,[163][164][165][166][167].…”

Section: Egfr Positive Lung Carcinomamentioning

confidence: 99%

Updates on liquid biopsy: current trends and future perspectives for clinical application in solid tumors

Pinzani

D’Argenio

et al. 2021

Clinical Chemistry and Laboratory Medicine (CCLM)

View full text Add to dashboard Cite

Despite advances in screening and therapeutics cancer continues to be one of the major causes of morbidity and mortality worldwide. The molecular profile of tumor is routinely assessed by surgical or bioptic samples, however, genotyping of tissue has inherent limitations: it represents a single snapshot in time and it is subjected to spatial selection bias owing to tumor heterogeneity. Liquid biopsy has emerged as a novel, non-invasive opportunity of detecting and monitoring cancer in several body fluids instead of tumor tissue. Circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), RNA (mRNA and microRNA), microvesicles, including exosomes and tumor “educated platelets” were recently identified as a source of genomic information in cancer patients which could reflect all subclones present in primary and metastatic lesions allowing sequential monitoring of disease evolution. In this review, we summarize the currently available information concerning liquid biopsy in breast cancer, colon cancer, lung cancer and melanoma. These promising issues still need to be standardized and harmonized across laboratories, before fully adopting liquid biopsy approaches into clinical practice.

show abstract

Section: Egfr Positive Lung Carcinomamentioning

confidence: 99%

Updates on liquid biopsy: current trends and future perspectives for clinical application in solid tumors

Pinzani

D’Argenio

et al. 2021

Clinical Chemistry and Laboratory Medicine (CCLM)

View full text Add to dashboard Cite

show abstract

“…Platelets are anucleate cells originating from megakaryocytes in bone marrow, known for their role in hemostasis and thrombosis. Despite that, platelets have emerged as having a major impact in both progression and spreading of several solid tumors, including LC (55,56). Tumor growth, progression and spreading require specific changes in tumor cells and in the surrounding microenvironment, being many of them similar to the physiological role of platelets (55).…”

Section: Tumor-educated Plateletsmentioning

confidence: 99%

The Role of Liquid Biopsy in Early Diagnosis of Lung Cancer

et al. 2021

View full text Add to dashboard Cite

Liquid biopsy is an emerging technology with a potential role in the screening and early detection of lung cancer. Several liquid biopsy-derived biomarkers have been identified and are currently under ongoing investigation. In this article, we review the available data on the use of circulating biomarkers for the early detection of lung cancer, focusing on the circulating tumor cells, circulating cell-free DNA, circulating micro-RNAs, tumor-derived exosomes, and tumor-educated platelets, providing an overview of future potential applicability in the clinical practice. While several biomarkers have shown exciting results, diagnostic performance and clinical applicability is still limited. The combination of different biomarkers, as well as their combination with other diagnostic tools show great promise, although further research is still required to define and validate the role of liquid biopsies in clinical practice.

show abstract

“…TEP was recently discovered as a potential noninvasive biomarker, as TEPs are involved in the initiation, progression, and metastasis of tumors [37,38]. Cancer cells induce platelet activation and assist the production of TEPs, which can promote tumor cell invasion through regulation of the p38MAPK-MMP9 pathway, promoting metastasis through EMT and escaping immunity via platelets-coated CTCs [39]. Also, alteration in a panel of RNAs was observed in cancers, which could also be useful as a biomarker [40].…”

Section: Biosources For Liquid Biopsymentioning

confidence: 99%

Liquid biopsy using extracellular vesicle–derived DNA in lung adenocarcinoma

Kim

Hur

Kim

et al. 2020

J Pathol Transl Med

View full text Add to dashboard Cite

A growing trend in identifying biomarkers in diseases has brought on a dramatic rise in the number of tissue biopsies performed in the era of precision medicine. With advanced non-small cell lung cancer (NSCLC) patients often relying on small biopsies, the clinical need for an established liquid biopsy protocol has become an urgent necessity. Unlike gastrointestinal cancer, where tumor lesions in all locations can generally be visualized, lung cancers can only be approached by bronchoscopy, which limits visualization to central tumors. Even with the use of endobronchial ultrasound, peripheral lung cancers, such as adenocarcinoma before metastasis to the mediastinal lymph node, must rely on the invasive percutaneous needle biopsy (PCNB). Recent trends have shown a decrease in the incidence of central lung cancers, such as squamous cell carcinoma and small cell carcinoma, with a concomitant increase in the incidence adenocarcinoma, where testing to identify driver oncogenic mutations is essentially useful [1-3]. With the development of target therapy drugs, the clinical need for rebiopsy or even repeated biopsies is increasing in order to identify drug resistance mechanisms in the targeted tissues [4,5]. Lung cancer tumor lesions are often small in size or positioned in a way that makes them difficult to target. In the case of ground-glass nodules (GGNs), a biopsy is not possible until enough of a solid portion develops to obtain tumor tissue by PCNB. For these reasons, "tissue is the issue" is a challenge faced by many clinicians, especially by those treating lung cancers. Liquid biopsy using blood was introduced to over

show abstract

Tumor-educated platelet as liquid biopsy in lung cancer patients

Cited by 31 publications

References 74 publications

Updates on liquid biopsy: current trends and future perspectives for clinical application in solid tumors

Updates on liquid biopsy: current trends and future perspectives for clinical application in solid tumors

The Role of Liquid Biopsy in Early Diagnosis of Lung Cancer

Liquid biopsy using extracellular vesicle–derived DNA in lung adenocarcinoma

Contact Info

Product

Resources

About